- •The percentage of patients diagnosed with stage I lung cancer is increasing.
- •This trend is observed in non−small-cell lung cancer but not in small-cell lung cancer.
- •The staging shift may be due to lung cancer screening and a higher detection of incidental lung nodules.
- •There are significant imbalances in the percentages of stage I lung cancer according to demographic characteristics.
The American Cancer Society has recently reported an increase in the percentage of patients with localized lung cancer from 2004 to 2018, coinciding with the initial lung cancer screening guidelines issued in 2013. We conducted a National Cancer Database (NCDB) study to further evaluate the trends in stage I according to patient and tumor characteristics.
We selected patients with lung cancer from the NCDB Public Benchmark Report diagnosed between 2010 and 2017. Patients with stages I to IV according to the AJCC seventh edition were evaluated according to the year of diagnosis, histology, age, sex, race, and insurance.
Among the 1,447,470 patients identified in the database, 56,382 (3.9%) were excluded due to stage 0 or unknown, or incorrect histology, leaving 1,391,088 patients eligible. The percentage of patients with stage I increased from 23.5% in 2010 to 29.1% in 2017 for all lung cancers, from 25.9% to 31.8% in non−small-cell lung cancer (NSCLC), and from 5.0% to 5.4% in small-cell lung cancer (SCLC). Patients younger than 70 years, males and blacks had lower percentages of stage I compared to older patients, females, and nonblacks respectively. Patients with no insurance had the lowest percentage of stage I.
There has been a significant increase in the percentage of stage I lung cancer at diagnosis from 2010 to 2017, which occurred mostly in NSCLC. Although the staging shift was observed in all subsets of patients, there were noticeable imbalances according to demographic factors.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Lung Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer statistics, 2022.CA Cancer J Clin. 2022; 72: 7-33
- Association of stage shift and population mortality among patients with non-small cell lung cancer.JAMA Netw Open. 2021; 4e2137508
- Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2014; 160: 330-338
- Reduced lung-cancer mortality with low-dose computed tomographic screening.N Engl J Med. 2011; 365: 395-409
- Lung screening benefits and challenges: a review of the data and outline for implementation.J Thorac Oncol. 2021; 16: 37-53
- Lung cancer screening rates during the COVID-19 pandemic.Chest. 2022; 161: 586-589
- Using the National Cancer Database for Outcomes Research: a review.JAMA Oncol. 2017; 3: 1722-1728
- Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.CA Cancer J Clin. 2011; 61: 212-236
- Cancer statistics, 2012.CA Cancer J Clin. 2012; 62: 10-29
- Cancer statistics, 2013.CA Cancer J Clin. 2013; 63: 11-30
- Cancer statistics, 2014.CA Cancer J Clin. 2014; 64: 9-29
- Cancer statistics, 2015.CA Cancer J Clin. 2015; 65: 5-29
- Cancer statistics, 2016.CA Cancer J Clin. 2016; 66: 7-30
- Cancer Statistics, 2017.CA Cancer J Clin. 2017; 67: 7-30
- The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.J Thorac Oncol. 2007; 2: 706-714
- The IASLC lung cancer staging project: proposals for revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.J Thorac Oncol. 2016; 11: 39-51
- Screening with low-dose computed tomography does not improve survival of small cell lung cancer.J Thorac Oncol. 2016; 11: 187-193
- International early lung cancer action program I. Small-cell carcinoma of the lung detected by CT screening: stage distribution and curability.Lung Cancer. 2012; 76: 339-343
- Characteristics and outcomes of small cell lung cancer detected by CT screening.Chest. 2018; 154: 1284-1290
- Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study.BMJ. 2022; 376e069008
- Incidental diagnosis of asymptomatic non-small-cell lung cancer: a registry-based analysis.Clin Lung Cancer. 2016; 17 (e1): 62-67
- Incidentally diagnosed cancer and commonly preceding clinical scenarios: a cross-sectional descriptive analysis of English audit data.BMJ Open. 2019; 9e028362
- Recent trends in the identification of incidental pulmonary nodules.Am J Respir Crit Care Med. 2015; 192: 1208-1214
- Increased disparities in patients diagnosed with metastatic lung cancer following lung CT screening in the United States.Clin Lung Cancer. 2022; 23: 151-158
- Potential disparities by sex and race or ethnicity in lung cancer screening eligibility rates.Chest. 2021; 160: 341-350
- Screening for Lung Cancer: US preventive services task force recommendation statement.JAMA. 2021; 325: 962-970
- Gender and lung cancer-SEER-based analysis.Ann Epidemiol. 2020; 46: 14-19
- American Thoracic Society Disparities in Healthcare G. An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes.Am J Respir Crit Care Med. 2010; 182: 1195-1205
- Predictors of lung cancer screening utilization in a population-based survey.J Am Coll Radiol. 2020; 17: 1591-1601
- Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer.N Engl J Med. 2022; 386: 1973-1985
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomized, multicentre, open-label, phase 3 trial.Lancet. 2021; 398: 1344-1357
Published online: November 20, 2022
Accepted: November 10, 2022
Received in revised form: November 2, 2022
Received: August 26, 2022
© 2022 Elsevier Inc. All rights reserved.